"...announced today that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019."
und gleich darauf :
Barclays Gene Editing & Gene Therapy Summit Nov 13, 2019 at 2:45 PM EST to Nov 13, 2019 at 12:00 AM EST Add to Outlook Add to Google Calendar Location New York, NY Speaker: Matt Kane, Chief Executive Officer
"Mr. Buehler has over thirty years of experience in the healthcare industry. He spent the majority of his career with Alcon Laboratories, a publicly traded ophthalmology-focused healthcare company headquartered in Fort Worth, Texas. At Alcon, Mr. Buehler rose through the commercial organization, eventually becoming CEO, leading the company?s sale to Novartis and subsequently serving as Alcon division head within Novartis. He will assume the chairmanship of Precision?s Nominating and Corporate Governance Committee (replacing Mr. Kane), and will also join the company?s Audit Committee (replacing Dr. Adelman)."
CRSP Market Cap 2.94B CRISPR Therapeutics AG DTIL Market Cap 453.90M Precision BioSciences, Inc. NTLA Market Cap 669.96M Intellia Therapeutics, Inc. EDIT Market Cap 1.16B Editas Medicine, Inc. SRPT Market Cap 7.28B Sarepta Therapeutics, Inc.
Da ist in der Tat noch viel Potenzial nach oben !!
"As of late, it has definitely been a great time to be an investor inPrecision BioSciences, Inc. DTIL. The stock has moved higher by more than 100% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path."
"....The abstract outlining initial data from patients treated with PBCAR0191 at Dose Level 1 can be accessed on the ASH conference website. Data in the abstract include results as of the cutoff date of August 1, 2019 for three patients with advanced NHL treated at Dose Level 1. No significant toxicities were observed, including no serious adverse events and no dose-limiting toxicities. All patients had a minimum follow-up of 28 days (median 60 days). Two of the three patients experienced an objective tumor response by Lugano criteria, at day 14 and day 28, respectively. The third patient, who had previously progressed following treatment with axicabtagene ciloleucel (Yescarta®), an approved anti-CD19 autologous CAR T therapy, had not met the definition of response, but demonstrated evidence of central necrosis, decreased tumor size, and decreased PET-avidity at day 28, in the context of post-infusion tumor site pain and mild CRS symptoms. Peripheral blood analysis for CAR T cell expansion has identified preliminary evidence of cell expansion."
Ich bin eigentlich guter Dinge, habe aber auch schon oft daneben gelegen.
Viele Mitstreiter schein es ja hier nicht zu geben.